Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Atkins

Showing results (241-250 of 493) with videos related to

Pageof 50
Sort By:
Frontiers in Oncology|January 31, 2022
Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint TherapyAidan M Burke, Michael Carrasquilla, Walter C Jean, et al.
Blood|November 15, 1990
Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effectsJ W Mier, G Vachino, M S Klempner, et al.
Cancer|October 7, 2015
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinomaSekwon Jang, Chaoyi Zheng, Huei-Ting Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptorD F McDermott, E G Trehu, J W Mier, et al.
AJR. American Journal of Roentgenology|June 20, 2008
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapyAdeel Sabir, Rachel Schor-Bardach, Carol J Wilcox, et al.
Thyroid : Official Journal of the American Thyroid Association|May 14, 2014
Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?Gauri R Khorjekar, Douglas Van Nostrand, Carlos Garcia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2022
The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring SteroidsNeil J Shah, Michael R Cook, Tianmin Wu, et al.
JCO Oncology Practice|July 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint InhibitorsCharlene M Mantia, Opeyemi A Jegede, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696J M Kirkwood, J Ibrahim, D H Lawson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinomaJared A Gollob, Korina G Veenstra, Robert A Parker, et al.
Pageof 50

Showing results (241-250 of 493) with videos related to

Sort By:
Pageof 50
Frontiers in Oncology|January 31, 2022
Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint TherapyAidan M Burke, Michael Carrasquilla, Walter C Jean, et al.
Blood|November 15, 1990
Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effectsJ W Mier, G Vachino, M S Klempner, et al.
Cancer|October 7, 2015
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinomaSekwon Jang, Chaoyi Zheng, Huei-Ting Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptorD F McDermott, E G Trehu, J W Mier, et al.
AJR. American Journal of Roentgenology|June 20, 2008
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapyAdeel Sabir, Rachel Schor-Bardach, Carol J Wilcox, et al.
Thyroid : Official Journal of the American Thyroid Association|May 14, 2014
Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?Gauri R Khorjekar, Douglas Van Nostrand, Carlos Garcia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2022
The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring SteroidsNeil J Shah, Michael R Cook, Tianmin Wu, et al.
JCO Oncology Practice|July 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint InhibitorsCharlene M Mantia, Opeyemi A Jegede, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696J M Kirkwood, J Ibrahim, D H Lawson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinomaJared A Gollob, Korina G Veenstra, Robert A Parker, et al.
Pageof 50